Prof. Tyler urged his students and colleagues "not only to seek the truth but, after finding it, to discard any preconceived ideas which it may reveal as untrue;" encouraged scientific and product integrity; and envisioned a rational herbal healthcare sector that valued the proper evaluation of products' quality, safety, and efficacy.
According to Suter, Bioforce spends 4 to 5% of annual sales income on clinical research each year. The company's main focus is researching the effect that echinacea (Echinacea spp.) and saw palmetto (Serenoa repens) have on common colds, infectious diseases of the upper respiratory tract, and benign prostatic hyperplasia, as well as herbal treatments for rheumatologic conditions and digestive disorders.
Bioforce has conducted at least 36 scientific studies on its products, the majority of which were published in scientific, peer-reviewed journals. Fourteen of these studies were carried out on its flagship product, Echinaforce®, an organic tincture of E. purpurea herb and root that is used to treat colds and flu. In 2006, an echinacea meta-analysis by Suter and fellow Bioforce AG scientist Roland Schoop was chosen as one of the top 25 research papers by the Annual Bibliography of Significant Advances in Dietary Supplement Research, published by the US National Institutes of Health Office of Dietary Supplements.
Additionally, according to Bioforce USA's Managing Director Eileen Sheets, Bioforce's arnica gel was the first product to obtain a traditional herbal registration from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), and of the approximate 120 registrations that MHRA has granted, about a quarter of them have been given to Bioforce products.
"We are fascinated by medical plants
|SOURCE American Botanical Council|
Copyright©2010 PR Newswire.
All rights reserved